Capital & Planning LLC’s Moderna MRNA Stock Holding History

Capital & Planning LLC’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-5	Closed	-$208	–	120
2024 Q4	$208	Buy	+5	New	+$239	﹤0.01%	187

Other funds holding MRNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital & Planning LLC's MRNA Position: Q1 2025 in Review

Capital & Planning LLC sold out of Moderna (MRNA) in Q1 2025, closing a stake of 5 shares — an estimated $208 sold.

Capital & Planning LLC first reported a position in MRNA in Q4 2024 and held it in 1 quarter. The position peaked at $208 in Q4 2024. 693 funds tracked by Wall St. Rank hold MRNA as of Q1 2025.

Capital & Planning LLC reported no remaining Moderna position as of Q1 2025 after selling out during the quarter.
Capital & Planning LLC sold 5 Moderna shares in Q1 2025, an estimated $208.
Capital & Planning LLC first reported a position in Moderna in Q4 2024 and held it in 1 quarter.
Capital & Planning LLC's Moderna position peaked at $208 in Q4 2024.
693 funds tracked by Wall St. Rank held Moderna as of Q1 2025.

Based on Capital & Planning LLC's 13F filing for Q1 2025, filed 16 May 2025.